Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20108048rdf:typepubmed:Citationlld:pubmed
pubmed-article:20108048lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:20108048lifeskim:mentionsumls-concept:C0004238lld:lifeskim
pubmed-article:20108048lifeskim:mentionsumls-concept:C1521761lld:lifeskim
pubmed-article:20108048lifeskim:mentionsumls-concept:C0444706lld:lifeskim
pubmed-article:20108048lifeskim:mentionsumls-concept:C1880594lld:lifeskim
pubmed-article:20108048pubmed:issue3lld:pubmed
pubmed-article:20108048pubmed:dateCreated2010-3-11lld:pubmed
pubmed-article:20108048pubmed:abstractTextAlthough atrial fibrillation (AF) is associated with increased morbidity and mortality from heart failure, stroke and other thromboembolic complications, there are limited data on its health-related quality of life (HRQoL) effects. The objective was to analyse the factors determining utility in patients with all types of AF, both at baseline and after 1 year from inclusion, based on data from the Euro heart survey.lld:pubmed
pubmed-article:20108048pubmed:languageenglld:pubmed
pubmed-article:20108048pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20108048pubmed:citationSubsetIMlld:pubmed
pubmed-article:20108048pubmed:statusMEDLINElld:pubmed
pubmed-article:20108048pubmed:monthAprlld:pubmed
pubmed-article:20108048pubmed:issn1573-2649lld:pubmed
pubmed-article:20108048pubmed:authorpubmed-author:LindgrenPeter...lld:pubmed
pubmed-article:20108048pubmed:authorpubmed-author:NieuwlaatRobb...lld:pubmed
pubmed-article:20108048pubmed:authorpubmed-author:CrijnsHarryHlld:pubmed
pubmed-article:20108048pubmed:authorpubmed-author:BergJennyJlld:pubmed
pubmed-article:20108048pubmed:authorpubmed-author:BouinOlivierOlld:pubmed
pubmed-article:20108048pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20108048pubmed:volume19lld:pubmed
pubmed-article:20108048pubmed:ownerNLMlld:pubmed
pubmed-article:20108048pubmed:authorsCompleteYlld:pubmed
pubmed-article:20108048pubmed:pagination381-90lld:pubmed
pubmed-article:20108048pubmed:meshHeadingpubmed-meshheading:20108048...lld:pubmed
pubmed-article:20108048pubmed:meshHeadingpubmed-meshheading:20108048...lld:pubmed
pubmed-article:20108048pubmed:meshHeadingpubmed-meshheading:20108048...lld:pubmed
pubmed-article:20108048pubmed:meshHeadingpubmed-meshheading:20108048...lld:pubmed
pubmed-article:20108048pubmed:meshHeadingpubmed-meshheading:20108048...lld:pubmed
pubmed-article:20108048pubmed:meshHeadingpubmed-meshheading:20108048...lld:pubmed
pubmed-article:20108048pubmed:meshHeadingpubmed-meshheading:20108048...lld:pubmed
pubmed-article:20108048pubmed:meshHeadingpubmed-meshheading:20108048...lld:pubmed
pubmed-article:20108048pubmed:meshHeadingpubmed-meshheading:20108048...lld:pubmed
pubmed-article:20108048pubmed:meshHeadingpubmed-meshheading:20108048...lld:pubmed
pubmed-article:20108048pubmed:meshHeadingpubmed-meshheading:20108048...lld:pubmed
pubmed-article:20108048pubmed:year2010lld:pubmed
pubmed-article:20108048pubmed:articleTitleFactors determining utility measured with the EQ-5D in patients with atrial fibrillation.lld:pubmed
pubmed-article:20108048pubmed:affiliationInstitute of Environmental Medicine, Karolinska Institute, Solna, Sweden. jenny.berg@ki.selld:pubmed
pubmed-article:20108048pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20108048pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed